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The transcription of cytomegalovirus (CMV) immediate-early (IE) genes is regulated by a large and complex
enhancer containing an array of binding sites for a variety of cellular transcription factors. Previously, using
bacterial artificial chromosome recombinants of the virus genome, it was reported that the enhancer region of
murine CMV (MCMV) is dispensable but performs a key function for viral multiplication (A. Angulo, M.
Messerle, U. H. Koszinowski, and P. Ghazal, J. Virol. 72:8502–8509, 1998). In the present study, we defined,
through the reconstitution of infectious enhancerless MCMVs, the growth requirement for the enhancer in
tissue culture and explored its significance for steering a productive infection in vivo. A comparison of cis and
trans complementation systems for infection of enhancerless virus in permissive fibroblasts revealed a multi-
plicity-dependent growth phenotype that is severely compromised in the rate of infectious-virus multiplication.
The in vivo impact of viruses that have an amputated enhancer was investigated in an extremely sensitive
model of MCMV infection, the SCID mouse. Histological examination of spleens, livers, lungs, and salivary
glands from animals infected with enhancer-deficient MCMV demonstrated an absence of tissue damage
associated with CMV infection. The lack of pathogenic lesions correlated with a defect in replication compe-
tence. Enhancerless viruses were not detectable in major target organs harvested from SCID mice. The
pathogenesis and growth defect reverted upon restoration of the enhancer. Markedly, while SCID mice infected
with 5 PFU of parental MCMV died within 50 days postinfection, all mice infected with enhancerless virus
survived for the duration of the experiment (1 year) after infection with 5  105 PFU. Together, these results
clarify the importance of the enhancer for MCMV growth in cell culture and underscore the in vivo significance
of this region for MCMV virulence and pathogenesis.
Following infection of permissive cells, cytomegalovirus
(CMV) expresses 200 viral products in a temporally regu-
lated fashion, presenting a cascadelike effect in which three
phases can be distinguished (for a review, see reference 28).
The immediate-early (IE) genes are the first genes to be ex-
pressed during infection, and their transcription is not depen-
dent on de novo protein synthesis. The production of IE gene
products is necessary for the transition into the early and late
phases (14). The genomic region of CMV, by far the most
actively transcribed at IE times, is called the major IE (MIE)
region. The basic structural organization of the MIE gene
locus exhibits a high degree of similarity among the different
members of the CMV family studied to date (35). A complex
and strong regulatory region, the MIE promoter (MIEP), gov-
erns the expression of the MIE genes, encoding the cotrans-
activator IE1 and the main early gene transactivator IE2 in
human CMV (HCMV) and IE3 in murine CMV (MCMV) (15,
16, 26; for an overview, see reference 28). The ie1 genes of both
HCMV and MCMV have been disrupted within the context of
the viral genome and shown to play nonessential roles in viral
replication in tissue culture, although under conditions of low
multiplicity of infection (MOI) CMVs defective in ie1 are com-
promised in the ability to replicate (12, 27, 29). A recent study
reported the generation of ie3-deficient mutants and showed
that the IE3 protein has an essential regulatory function during
the lytic replication cycle of MCMV in tissue culture, being
absolutely required for viral replication and lytic gene expres-
sion (1). To date, despite the efforts of several groups, it has
not been possible to recover an HCMV IE2-defective virus
from HCMV genomes with ie2 deleted, indicating that, similar
to its murine homolog, IE2 is required for successful HCMV
infection in tissue culture (22).
Due to the crucial role played by the MIE proteins during
viral infection, regulation of the MIEP has been speculated to
be a critical stage in determining CMV permissiveness and
switching between latent and lytic infections (18). Transcrip-
tional control of the MIEP comprises a complex interplay
between both positive and negative cis-acting regulatory ele-
ments (24). The HCMV MIEP consists of several distinct func-
tional units, including a basal promoter, modulator sequences,
and a highly potent enhancer containing most of the regulatory
elements (reviewed in reference 11). The HCMV enhancer
carries reiterated binding sites for a large repertoire of host
transcription factors, the majority of which are regulated
through signal transduction mechanisms. These cis-acting ele-
ments include, among others, binding sites for the transcrip-
tion factors AP-1, CREB/ATF, NF-B, retinoic acid receptors,
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and Sp1. Viral proteins, like the tegument protein pp71 and
IE1 (7, 20), have also been reported to regulate the activity of
the HCMV MIEP. In addition, cellular transcription factors
such as YY1 can repress HCMV enhancer function (21). Anal-
ogous MIE enhancers are present in other animal CMV ge-
nomes. However, the organization of this region is quite dif-
ferent among CMVs, with variations in the nature, number,
and arrangement of the consensus transcription factor sites
that they carry (5, 6, 8, 33).
For years, most of our understanding of the significance and
regulation of the HCMV-MIEP enhancer has been derived
from in vitro transcription and transient-transfection assays.
Work with HCMV-MIEP transgenic-mouse models first indi-
cated the importance of the enhancer in conferring cell-type-
specific activity in vivo. In these animal models, the expression
of the enhancer mimics in part tissues and cell types naturally
infected by HCMV (3, 4, 17). More recently, studies with
enhancer swap viruses in which the native enhancer of MCMV
or rat CMV has been replaced with that of HCMV or MCMV
have indicated that the enhancer region is not responsible for
species specificity and that the enhancers are paralogous in
function (2, 13, 34). Despite some phenotypic differences de-
pendent on the origin of the enhancer, enhancer swap viruses
are able to grow in vitro as well as in their respective hosts,
suggesting very similar modes of action among enhancer se-
quences from distinct CMV strains. However, the biological
relevance of the MIEP enhancer was not directly addressed
until the generation of CMV genomes lacking enhancer se-
quences. It was previously shown that enhancerless MCMV
bacterial artificial chromosome (BAC) genomes, when trans-
fected into murine fibroblasts, led to viral progeny, although
substantially reduced compared to that originating from the
parental MCMV BAC genome (2). In agreement with these
results, HCMV recombinants lacking the MIE distal enhancer
region are partially debilitated in their growth on fibroblasts,
exhibiting an MOI-dependent effect (23). From these obser-
vations, we can infer that for a productive CMV infection of
permissive fibroblasts, enhancer elements are not strictly nec-
essary. However, a fundamental question that still remains
unanswered is to what extent the MIEP enhancer region con-
tributes to growth and pathogenesis during a natural CMV
infection.
To unequivocally define the role of enhancer-mediated tran-
scription control of the MIE locus during viral replication in
vitro and to investigate the contribution of this region to
MCMV in vivo growth and pathogenesis, we have isolated
enhancerless MCMV recombinants with the aid of a comple-
menting cell system. We demonstrate that resection of the
enhancer remarkably reduces MCMV replication at low MOIs
but not at high MOIs in cultured murine fibroblasts. Studies of
severe combined immunodeficient (SCID) mice indicate that
enhancer sequences are required for MCMV growth in target
organs. Moreover, recombinant viruses with the MIE enhancer
deletion exhibit a severely attenuated phenotype. This work
provides the long-awaited evidence showing that the MCMV
enhancer is absolutely required for efficient replication, patho-
genesis, and virulence in its natural host.
(Part of these results was presented at the 25th International
Herpesvirus Workshop in Portland, Oregon, July and August
2000.)
MATERIALS AND METHODS
Cells and viruses. Mouse NIH 3T3 cells (ATCC CRL1658) were grown in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% new-
born calf serum. Primary mouse embryonic fibroblasts were prepared from
BALB/c.ByJ mice and grown in DMEM with 10% fetal calf serum. The parental
BAC-derived MCMV strain MW97.01 (36; called MCMV in this study) and
MCMVdE::Luc-rev were propagated on NIH 3T3 cells. The enhancerless mu-
tants, MCMVdE and MCMVdE::Luc, were grown on the complementing cell
line NIH 3T3-Bam25.
Construction of NIH 3T3-Bam25 cells. NIH 3T3-Bam25 cells were derived
from NIH 3T3 cells by cotransfecting pAMB25 (15; referred to as pBam25 in this
publication), a plasmid containing the MCMV ie1 and ie3 genes (nucleotides [nt]
176441 to 187035 of the MCMV genome [32]), and pPUR (Clontech, Palo Alto,
Calif.), a plasmid containing the puromycin resistance gene, using the calcium
phosphate technique (10) and selecting cells in medium containing puromycin
(Sigma) at 5 g/ml. The cultures were refed every 3 to 5 days. Single colonies
were picked using cloning cylinders and analyzed for IE1 expression by indirect
immunofluorescence using the monoclonal antibody Croma 101 (kindly provided
by Stipan Jonjic). RT PCR using specific primers for ie1 (ie1-R [5-TAC AGG
ACA ACA GAA CGC TC-3] and ie1/3-F [5-CCT CGA GTC TGG AAC CGA
AA-3]) and ie3 (ie3-R [5-TGT GAG GCA GTA GTT ATA CC-3] and ie1/3-F
[19]) was carried out to confirm the presence of ie1 and ie3 transcripts in NIH
3T3-Bam25 cells. Several lines were obtained. For the purpose of this study, we
primarily used clone 23.
Analysis of viral growth in vitro. Monolayers of NIH 3T3 cells or NIH 3T3-
Bam25 cells in 24-well dishes were infected at an MOI of 3 (for single-cycle
growth curves) or 0.01 (for multicycle growth curves) PFU/cell with the different
MCMV recombinants. After a 1-h adsorption period, the cells were washed three
times with phosphate-buffered saline and fed with fresh medium. At different
times after infection, the supernatants of three different cultures were harvested,
cleared of cellular debris, frozen, and thawed. Viral titers were determined by
standard plaque assays (without centrifugal enhancement of infectivity) on NIH
3T3-Bam25 cells. The nature of the enhancerless viruses resulting from growth
curves performed at high MOIs on NIH 3T3 cells was checked by parallel
titration of the samples on NIH 3T3 cells and the complementing cell line, taking
advantage of the different plating efficiencies of enhancerless viruses in these two
cell types. Data were plotted as viral titers (PFU/ml) versus time postinfection (in
days). After evaluation of the plots, growth constants were determined for the
exponential phase of viral growth. Data points from days 1 to 3 after infection
were used, except for enhancerless viruses under low-MOI conditions, for which
days 3 to 5 after infection were considered for the analysis because a phase shift
of exponential growth was observed in these cases. An exponential regression
model of type y  b  emx was used to determine the parameters and quality of fit
for the untransformed data. Parameter b is the intercept for the curve, and
parameter m is the slope and therefore the exponential-growth rate constant.
Computations were performed in Excel using the LOGEST function for expo-
nential regression.
Plasmid construction. Construction of the shuttle plasmids required for in-
troduction of the enhancer deletion and replacement of the enhancer sequences
by a stuffer fragment, respectively, in the BAC-cloned MCMV genome has been
described previously (2). Briefly, the shuttle plasmid pMBO-dEnh carries an
8.0-kbp fragment comprising the MCMV sequences (32) from nt 178736 to
182940 (SpeI to EspI) and 184086 to 187889 (NdeI to HindIII). Thus, the frag-
ment provides the homologous viral DNA sequences needed to delete the
MCMV enhancer sequences from nt 182940 (EspI) to 184086 (NdeI). The shuttle
plasmid pST76A-luc carries the same MCMV DNA sequences and in addition a
770-bp fragment of the luciferase gene (referred to as the luciferase stuffer)
inserted between the EspI (nt 182940) and NdeI (nt 184086) sites, replacing the
MCMV enhancer sequences. For the construction of a revertant virus genome,
we decided to tag the MCMV enhancer sequences in order to allow differenti-
ation between the genomes of the revertant and the parental viruses. A 22-bp
oligonucleotide linker (forward, 5-GGC AAG CTT GCG ATG CCT GGA T-3;
reverse, 5-CCA GGC ATC GCA AGC TTG CCA T-3) providing a HindIII site
(underlined) was inserted into the unique PacI site (MCMV nucleotide position
183155) of the plasmid pUC-L (2). Then, a 5.3-kbp ApaI/SfiI fragment was
transferred to the ApaI/SfiI-digested plasmid pST76A-luc, resulting in the shuttle
plasmid pST76A-RevH1.
BAC mutagenesis and reconstitution of MCMV mutants. Recombination be-
tween the BAC plasmid pSM3fr containing the complete MCMV genome (re-
ferred to as C3X in this publication) (36) and the shuttle plasmids pMBO-dEnh
and pST76A-luc was performed by a two-step replacement procedure in the
Escherichia coli strain CBTS as described previously (2, 36) in order to generate
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the mutant MCMV BAC plasmids C3XdE and C3XdE::Luc, respectively. The
shuttle plasmid pST76A-RevH1 and the BAC plasmid C3XdE::Luc were used to
generate the BAC plasmid C3XdE::Luc-rev, which contains the repaired en-
hancer sequences. Recombinant viruses were reconstituted by transfection of the
BAC plasmids into NIH 3T3 cells or the complementing cell lines using the
calcium phosphate transfection method.
Viral nucleic acid isolation and analysis. Preparation of total DNA from
infected cells, restriction enzyme analysis, and gel electrophoresis were done
essentially as described previously (2). BAC plasmids were isolated from 400-ml
E. coli cultures by using Nucleobond PC 100 columns (Machery-Nagel, Du¨ren,
Germany) according to the instructions of the manufacturer. To analyze whether
appropriate excision of the BAC vector sequences from the recombinant MCMV
genomes had occurred, PCRs were carried out as described previously (36).
Primers b (5-GCC CGC CTG ATG AAT GCT C-3) and g (5-GGA TAC TCA
GCG GCA GTT TGC-3), which bind in the BAC vector sequences and in the
EcoRI g fragment, respectively, were used to detect a 1,950-bp PCR fragment
within the BAC-containing genomes. Primers f (5-GGT TAC TGG ATG GGT
ACG AG-3) and g, which bind to viral sequences flanking the excision site, were
used to amplify a 590-bp product after successful excision of the BAC vector
from the viral genomes. The template used in the PCR was either genomic DNA
from cells infected with the recombinant viruses or viral genomes from extracel-
lular virus (105 PFU) that was heated at 95°C for 5 min before being added to the
reaction mixture. PCRs were performed under the following conditions: 1 cycle
at 94°C for 3 min; 30 cycles of 1 min at 94°C, 1 min at 51°C, and 1 min at 72°C;
and 1 cycle at 72°C for 10 min.
Infection of immunocompromised mice. Female CB17 SCID mice (6 weeks
old) were obtained from Taconic Farms and housed in the vivarium (The Scripps
Research Institute) under specified pathogen-free conditions. The animals were
injected intraperitoneally with 6  105 PFU of tissue culture-derived MCMV
recombinants. On various days after infection, mice were sacrificed and organs
were removed, weighed, and harvested as a 10% (wt/vol) tissue homogenate, and
virus titers were determined on NIH 3T3-Bam25 cells by standard plaque assay.
To maximize sensitivity, samples from animals infected with enhancerless virus
and in which infectious virus could not be detected by standard plaque assays
were also titrated using centrifugal enhancement of infectivity. To assess levels of
virulence, the lethalities in CB17 SCID mice of recombinant and parental
MCMV viruses were compared. Animals were infected intraperitoneally with
various amounts of tissue culture-passaged recombinant or parental wild-type
virus, and their survival was monitored daily for at least 150 days after infection.
Histopathology. Six-week-old female CB17 SCID mice were injected intra-
peritoneally with 6  105 PFU of tissue-culture-derived MCMV recombinants.
At 14 days after infection, the mice were sacrificed and selected organs were
removed and fixed in Bouin’s solution. The fixed tissues were subsequently
processed and embedded in paraffin by standard procedures. The organs and
tissues included the spleen, liver, lung, and salivary gland. Sections (3 m thick)
were cut with a rotary microtome and stained with hematoxylin and eosin for
examination. In addition to routine examination and qualitative assessment of
selected tissues, liver sections were examined using the 10 objective to deter-
mine the number of inflammatory foci (10 inflammatory cells per focus) per
unit area.
RESULTS
Generation of enhancerless MCMV recombinants. Previ-
ously, the construction of MCMV genomes lacking enhancer
sequences, based on the parental MCMV BAC plasmid pSM3,
was reported (2). Viral progeny reconstituted from this paren-
tal BAC construct following transfection of permissive cells
exhibits an attenuated phenotype in vivo due to a deletion of
viral sequences and insertion of the BAC vector (36). Recently,
a BAC plasmid, pSM3fr (36; called C3X in this study), con-
taining the full-length MCMV genome was generated. Virus
reconstituted from this new construct after transfection into
permissive cells shows biological properties in vivo comparable
to those of wild-type MCMV. Since the purpose of this study
was to analyze the relevance of the enhancer region during an
acute CMV infection, we decided to generate new enhancer-
less MCMV genomes based on the C3X backbone. A sche-
matic representation of the various BAC recombinant ge-
nomes constructed is shown in Fig. 1. In order to remove the
MCMV enhancer sequences, a 1.1-kbp EspI-NdeI deletion was
introduced within the HindIII L fragment of the parental
MCMV genome C3X by using recombination techniques in E.
coli as described in Materials and Methods. The resulting BAC
recombinant genome, C3XdE, contained a deletion that en-
compasses nucleotide positions 	48 to 	1191 of the MCMV
MIEP. In this recombinant BAC plasmid, deletion of the 1.1-
kbp segment places nucleotide position	183 relative to the ie2
transcription start site immediately adjacent to nucleotide po-
sition 	48 of the MIEP. It is possible that in this recombinant
the remains of the MIEP could be influenced by the juxtapo-
sition of the ie2 promoter-proximal control elements, that the
junction point introduces a novel regulatory sequence, or that
the relative positional distance between the ie2 and MIEP
TATA boxes interferes with or modulates their activities. For
these reasons we sought to maintain spatial integrity of the
ie1-ie3 and ie2 promoters flanking the MIEP enhancer, and we
constructed a second BAC plasmid, C3XdE::Luc, that contains
a stuffer fragment replacing the deleted enhancer segment. In
C3XdE::Luc, a nonregulatory 770-bp fragment from the firefly
luciferase reporter gene was introduced within nucleotides
	48 to 	1191 of the enhancer region of MCMV. Finally, to
determine whether the phenotype of the enhancer-deficient
genome C3XdE::Luc was caused solely by deletion of the en-
hancer region, a revertant genome designated C3XdE::Luc-rev
was generated. In this recombinant BAC construct, the lucif-
erase stuffer present in C3XdE::Luc was replaced by the 1.1-
kbp segment of the natural MCMV enhancer (spanning nu-
cleotide positions 	48 to 	1191 of the MCMV MIEP). To
distinguish this new MCMV BAC plasmid from the parental
C3X genome, a new HindIII restriction site was introduced
within the HindIII L fragment (described in more detail in
Materials and Methods).
To verify the genomic structure of the recombinant BAC
plasmids generated, their HindIII restriction patterns were an-
alyzed. As shown in Fig. 2, the 7.2-kbp HindIII L fragment of
the parental BAC plasmid C3X was replaced by a 6.0-kbp
fragment in C3XdE (Fig. 2, compare lanes 1 and 2). Insertion
of the stuffer sequences into the BAC plasmid C3XdE::Luc led
to a shift of the 7.2-kbp HindIII L fragment to a novel fragment
of 6.7-kbp (Fig. 2, lanes 1 and 3). Restoration of the enhancer
sequences in the revertant BAC plasmid C3XdE::Luc-rev re-
sulted in the appearance of two new fragments of 2.4 and 4.7
kbp (Fig. 2, compare lanes 1 and 4). These findings confirmed
the successful deletion of the enhancer in C3XdE and
C3XdE::Luc and the correct introduction of the stuffer and
enhancer segments into the BAC plasmids C3XdE::Luc and
C3XdE::Luc-rev, respectively. Additional restriction enzyme
digest analyses (with EcoRI) indicated that the recombinant
BAC plasmids generated were as expected and that no dele-
tions or rearrangements had occurred elsewhere in the genome
(data not shown).
We next sought to reconstitute and isolate viral progeny
from the recombinant BAC constructs. Because in our previ-
ous experiments it became clear that enhancerless MCMV
BAC genomes produce significantly fewer plaques after trans-
fection into murine fibroblasts than wild type genomes, we
examined whether reconstitution of enhancerless viruses from
the recombinant BAC plasmids would be facilitated by the use
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of a complementing cell line expressing the MCMV IE pro-
teins IE1 and IE3. To this end, NIH 3T3 cells were trans-
fected with a recombinant plasmid, pBam25, which carries
the MCMV ie1 and ie3 genes, and stable NIH 3T3-Bam25
cell lines were isolated as described in Materials and Meth-
ods. The parental and revertant BAC plasmids C3X and
C3XdE::Luc-rev were transfected into NIH 3T3 cells, while
the enhancerless BAC plasmids C3XdE and C3XdE::Luc
were transfected into one of the NIH 3T3-Bam25 cell lines.
In all four cases, numerous plaques developed 5 to 6 days
posttransfection, and the infection spread rapidly through-
out the cultures, reaching a complete cytopathic effect 2 to
3 days later. These results are in agreement with our previ-
ous studies, indicating that the growth defect of enhancer-
less virus is due to a lack of transacting IE protein activity.
The supernatants derived from these cultures were used to
infect new cell monolayers, the corresponding viruses were
subsequently purified by three rounds of plaque purification,
and viral stocks were generated. For enhancerless MCMV
recombinants, NIH 3T3-Bam25 cells were used throughout
the amplification and purification steps. The viruses gener-
ated were named MCMV (derived from C3X), MCMVdE
(derived from C3XdE), MCMVdE::Luc (derived from
C3XdE::Luc), and MCMVdE::Luc-rev (derived from C3XdE::
Luc-rev).
The complementing cell line contains sequences from nt
176441 to 187035 of the MCMV genome, and the deletion of
the enhancer in the enhancerless genomes spans nt 	48 to
	1191. Therefore, there are sequences in the NIH 3T3-Bam25
cell line homologous to regions directly flanking the enhancer
segment. Homologous recombination between the shared se-
quences could potentially result in the generation of revertant
viruses due to the restoration of the enhancer segment. In
order to analyze the genomic structure of the reconstituted
mutants, and to confirm that during the replication process in
the complementing cell line the enhancerless viruses did not
acquire the missing enhancer sequences, total cell DNA was
isolated from infected cells and subjected to HindIII digestion.
In all four cases, the DNA patterns of the viral genomes cor-
rectly matched the predicted ones and proved to be identical to
those of the corresponding BAC plasmids (data not shown).
Thus, with the help of a complementing cell system we were
able to isolate and produce stocks of mutant MCMV lacking
the enhancer with which to analyze the biological phenotype.
Growth rates of enhancerless MCMV recombinants in tis-
sue culture: an evaluation in cis and trans complementation
FIG. 1. Construction of enhancerless MCMV BAC genomes. The HindIII map of the MCMV genome is shown at the top. The HindIII K and
L fragments from the parental MCMV BAC genome, C3X, are expanded below to show the major IE gene region. The structures of the ie1, ie2,
and ie3 transcripts are indicated below the expanded map. Coding exons are shown solid, and the first noncoding exons of the ie1-ie3 and ie2
transcription units are depicted as open rectangles. The shaded box marks the MCMV enhancer ie1-ie3 promoter. The recombinant MCMV BAC
plasmids C3XdE, C3XdE::Luc, and C3XdE::Luc-rev, shown below the C3X genome, were generated by successive rounds of homologous
recombination in E. coli starting from the parental BAC plasmid C3X (for C3XdE and C3XdE::Luc) or C3XdE::Luc (for C3XdE::Luc-rev), as
indicated in Materials and Methods. The MCMV BAC plasmid C3XdE contains a 1.1-kbp deletion within the HindIII L fragment extending from
nucleotide position	48 to	1191 relative to the ie1-ie3 MCMV transcription start site. C3XdE::Luc contains a 770-bp fragment from the luciferase
gene replacing nucleotide sequences from 	48 to 	1191 of the MCMV MIEP enhancer region. C3XdE::Luc-rev is a revertant of C3XdE:: Luc
in which the enhancer sequences were reconstituted. The 1.1-kbp deletion in the enhancer region is marked 
. The crosshatched box represents
the luciferase stuffer region. The sizes of the natural and new HindIII K and L fragments are indicated. The illustration is not drawn to scale.
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systems (in a functional context). The fact that we could prop-
agate and obtain relatively high titers of enhancerless mutants
with the aid of the complementing cell line allowed us to
characterize in more detail the growth properties of the en-
hancerless mutants in tissue culture. To this end, viral replica-
tion was examined after both high- and low-MOI infections of
NIH 3T3 cells and compared to that exhibited by the parental
or revertant virus. First, NIH 3T3 cells were infected with
recombinant MCMVs at an MOI of 0.01, and viral titers were
determined by standard plaque assays at various times postin-
fection. As shown in Fig. 3A, the amounts of virus that could
be detected in the supernatants of the cultures infected with
MCMVdE or MCMVdE::Luc were very small. Viral titers of
8  101 to 1  102 PFU/ml were obtained by day 5 postin-
fection. These results were consistent with previous data that
documented a reduced efficacy after transfection of enhancer-
less BAC genomes into permissive fibroblasts compared to
parental or revertant plasmids (2). In contrast, cultures that
were infected with viruses that contained the enhancer region
displayed a rapid increase in viral titers. Viral yields of 106
PFU/ml were reached in these cultures 5 days after infection.
The growth kinetics of the revertant virus MCMVdE::Luc-rev
were indistinguishable from those of the parental virus, dem-
onstrating that reinsertion of the enhancer region led to com-
plete rescue of the growth phenotype. These results ruled out
the possibility that other regions outside the enhancer were
responsible for the replication defect associated with the en-
hancer-deficient viruses, MCMVdE and MCMVdE::Luc, un-
der low-MOI conditions. To document further the replication
deficiency associated with enhancerless viruses under these
conditions, we calculated from the growth kinetics the expo-
nential-growth rate constants for the four recombinant viruses
as described in Materials and Methods. While the exponential-
growth rate constants were 3.17 days	1 and 3.05 days	1 for
parental and revertant MCMV, respectively, the correspond-
ing values for enhancerless MCMVs proved to be 0.47 days	1
for MCMVdE and 0.40 days	1 for MCMVdE::Luc. Thus, a
marked reduction of almost 10-fold in the rate constant of
exponential growth was observed after resection of the en-
hancer segment of MCMV, resulting in104-fold difference in
the production of infectious viral particles per milliliter. Alto-
gether, therefore, these data indicate that the enhancer region
makes a vital contribution to accelerating productive infection
when a low input of virus is used.
To examine whether the inefficient growth displayed by en-
hancerless viruses could be overcome by increasing the virus
dose, NIH 3T3 cells were infected at an MOI of 3. In these
single-step growth analyses, both MCMVdE and MCMVdE::
Luc presented slightly lower titers than enhancer-containing
viruses (1-log-unit difference in this experiment) by day 2 or
3 after infection (Fig. 3B). The differences in growth levels
between enhancer-deficient and enhancer-containing viruses
were statistically significant (P  0.01, as determined by Stu-
dent’s test) at the time point where the maximum difference
was observed. However, the final viral titers reached in cultures
infected with enhancerless MCMV were similar to those ob-
tained after infection with wild-type or revertant MCMV (Fig.
3B). In agreement with these observations, the exponential-
growth rate constants calculated under these high-MOI condi-
tions were 3.37 days	1 for parental MCMV, 3.15 days	1 for
MCMVdE::Luc-rev, 2.23 days	1 for MCMVdE, and 2.44
days	1 for MCMVdE::Luc. Thus, when high input doses of
enhancerless viruses were used, growth constants at the expo-
nential phase were very close (1.4- to 1.5-fold difference) to the
ones exhibited by enhancer-containing MCMVs. These find-
ings suggest that enhancer sequences from nt 	48 to 	1191
are dispensable for replication in cultured murine fibroblasts
under high-MOI conditions.
FIG. 2. Structural analysis of the enhancerless MCMV BAC ge-
nomes. DNAs of the HindIII-digested BAC plasmids C3X (lane 1),
C3XdE (lane 2), C3XdE::Luc (lane 3), and C3XdE::Luc-rev (lane 4)
after separation on a 0.7% agarose gel and ethidium bromide staining.
The HindIII fragment names (9) are shown at the left. The sizes of the
natural HindIII L and M fragments and the new HindIII L fragment
for each BAC plasmid are indicated with arrows at the right.
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We next carried out growth analysis on the NIH 3T3-Bam25
cell line to examine the extent to which the IE protein-com-
plementing system could restore replication of the enhancer-
less mutants under low-MOI conditions. When NIH 3T3-
Bam25 cells were infected at an MOI of 0.01 PFU/cell,
MCMVdE and MCMVdE::Luc grew with kinetics that, al-
though not identical, were comparable to those exhibited by
wild-type and revertant MCMVs (Fig. 3C). Altogether, these
data clearly indicate that the enhancerless virus phenotype is
multiplicity dependent and that the rate constant defect and
impaired growth exhibited under low-MOI conditions can be
mostly rescued by trans-complementation with IE protein ex-
pression.
Absence of MCMV-induced pathogenicity in SCID mice in-
fected with enhancer-deficient MCMV. In the next set of ex-
periments, we sought to address the role and biological signif-
icance of the enhancer in vivo. The parental MCMV BAC
plasmid, C3X, used for the generation of the mutants de-
scribed in this study contains the full-length MCMV genome.
In addition, the MCMV BAC plasmid contains an insertion of
BAC vector sequences flanked by short identical viral se-
quences that serve as a substrate for homologous recombina-
tion during virus reconstitution in cells, thus allowing the elim-
ination of all nonviral sequences. Excision of the BAC vector
via the duplicated sequences can be achieved in an accurate
and reproducible manner after five virus passages (36). Al-
though the BAC sequences within the MCMV genome have
been shown not to alter viral replication in tissue culture, they
might have some unpredictable effects during the course of an
infection in vivo. We therefore examined whether the viral
stocks generated, after the cloning and amplification steps to
which they were subjected, had appropriately excised the BAC
vector sequences. For this purpose, PCRs were performed
using two different primer sets with the recombinant viral ge-
nomes as templates (36; see Materials and Methods for further
details). First, reactions were carried out with a primer that
binds in the BAC vector sequences and a second primer that
anneals in the MCMV EcoRI fragment. This primer pair
should yield a 1,950-bp PCR fragment if the BAC vector seg-
ment was present within the viral genomes or fail to amplify a
product in the absence of these BAC sequences. As expected,
a specific PCR-amplified product was not obtained with this
primer set when the DNA from the recombinant viral stocks
was used as a template (Fig. 4, lines 1 to 4). In contrast, a
1,950-bp fragment could be detected in a DNA preparation
isolated from an early MCMVdE::Luc passage, examined be-
fore all the cloning and amplification steps (Fig. 4, line 5).
Thus, the data suggested that BAC-containing genomes were
not present in the recombinant viral stocks. Next, reactions
were performed with a set of primers that bind to viral se-
quences flanking the BAC excision site. This second primer set
should either fail to detect a product in the recombinant viral
genomes if the BAC sequences were present or yield a 590-bp
product in cases where the BAC vector had been appropriately
excised. As shown in Fig. 4, when DNA isolated from any of
the four viral recombinant stocks was used as a template in the
reactions, the expected 590-bp fragment was obtained (lanes 6
to 9), while no specific amplified product was detected when
FIG. 3. Growth curve analysis of enhancerless MCMV mutants in tissue culture. NIH 3T3 cells (A and B) or NIH 3T3-Bam25 cells (C) were
infected at an MOI of 0.01 (A and C) or 3 (B) PFU/cell with parental MCMV, MCMVdE, MCMVdE::Luc, and MCMVdE::Luc-rev. At the
indicated time points after infection, supernatants from the infected cultures were harvested, and titers were determined on monolayers of NIH
3T3-Bam25 cells. The error bars indicate the standard deviation of the viral titers from three separate cultures.
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DNA from an early MCMVdE::Luc passage was used (lane
10). Together, these results confirmed that our fibroblast-pas-
saged recombinant MCMV stocks were homogeneous and
their genomes were free of BAC vector sequences.
In initial experiments in which BALB/c mice were infected
with enhancerless viruses, we failed to detect any symptoms of
MCMV-associated disease or to recover any enhancerless in-
fectious virus (data not shown). To determine the extent to
which deletion of the enhancer affects viral pathogenesis and
replication in vivo, we turned to an extremely susceptible
model for MCMV infection, CB17 SCID mice. The selection
of such a system was based on the defective phenotype dis-
played by enhancerless MCMVs in vitro under low-MOI con-
ditions and the fact that SCID mice are highly sensitive to low
levels of infectious virus. CB17 SCID mice, which are devoid of
Ly49-NK cells and functional T and B lymphocytes, are inca-
pable of efficiently controlling an MCMV infection, succumb-
ing to as few as 1 PFU (30, 31). We first studied the pathoge-
nicities of the enhancerless MCMV recombinants in these
immunodeficient animals. For this pupose, histological exam-
ination of selected key organs following infection with enhanc-
erless viruses was carried out. SCID mice were injected intra-
peritoneally with 6  105 PFU of enhancerless, parental, or
revertant MCMV. Fourteen days postinfection, the mice were
sacrificed, and their livers, spleens, lungs, and salivary glands
were harvested. Tissue sections were prepared and stained
with hematoxylin and eosin for morphological examination.
Sections of the livers were analyzed first. As expected, CMV
infection-associated lesions were detected in the livers of wild-
type and revertant MCMV recombinant-infected mice (Fig. 5B
and D [revertant virus] and data not shown [wild-type virus]).
The lesions generally were characterized by the presence of
multifocal neutrophilic infiltrates, occasionally associated with
large cells with eosinophilic intranuclear Cowdry type A inclu-
sions, as well as eosinophilic intracytoplasmic inclusions (cyto-
megalic cells [Fig. 5B]). In addition, in the livers of affected
animals, the inflammation was often correlated with individual
hepatocellular necrosis (Fig. 5D). In marked contrast, the liv-
ers of mice infected with enhancerless virus were essentially
normal (Fig. 5A and C [MCMVdE::Luc] and data not shown
[MCMVdE]), and signs of CMV infection were not detected.
When spleens, lungs, and salivary glands of mice infected
with parental and revertant viruses were analyzed, damage
induced by CMV infection was detected in the three organs
(Fig. 5F, H, and J [revertant MCMV] and data not shown
[parental MCMV]). Again, lesions were associated with the
presence of multifocal neutrophilic infiltrates, occasionally cor-
related with large cells with eosinophilic intranuclear Cowdry
type A inclusions, as well as cytomegalic cells. Both the white
pulp and the red pulp of the spleens from these animals were
affected (Fig. 5F). The lungs were characterized by multifocal
interstitial and intra-alveolar neutrophilic infiltrates and focally
increased pulmonary macrophage numbers (Fig. 5H). In the
salivary glands, inflammation was associated with focal epithe-
lial necrosis, while cytomegalic cells at times were located away
from the inflammatory infiltrates (Fig. 5J). In contrast, signs of
CMV infection in these three organs were not detected in mice
infected with enhancerless virus (Fig. 5E, G, and I
[MCMVdE::Luc] and data not shown [MCMVdE]). Consis-
tent with these results, we were unable to detect damage in-
duced by CMV after examination of the livers, spleens, lungs,
and salivary glands of mice infected for 7 days with enhancer-
less MCMV (data not shown). From all these data together we
conclude that the enhancer region significantly contributes to
MCMV pathogenesis.
Loss of pathogenicity of enhancerless MCMV recombinants
is correlated with an inability to establish a productive infec-
tion in vivo. We next sought to analyze whether the lack of
virus-induced damage after infection by enhancerless MCMV
was due to the inability of these viruses to replicate in CB17
SCID mice. For these experiments, animals were injected in-
traperitoneally with 6 105 PFU of enhancerless, revertant, or
parental MCMV. At 7 days postinfection, spleens, livers, and
lungs were harvested, and virus titers in these three target
organs for MCMV replication were determined on NIH 3T3-
Bam25 cells. As shown in Fig. 6, under these conditions of
infection, the parental MCMV exhibited titers of 2  104, 3
 103, and 1  103 PFU/g in the spleen, liver, and lungs,
respectively. Conversely, replication of the enhancerless vi-
ruses, MCMVdE and MCMVdE::Luc, could not been de-
tected in these three organs (Fig. 6). As expected, the revertant
virus MCMVdE::Luc-rev was found to replicate at levels sim-
ilar to those of the parental MCMV in the three organs, con-
firming that the enhancerless phenotype was indeed due to the
absence of the enhancer sequences. Titers of revertant virus in
the spleens, livers, and lungs of the SCID mice were 3  104,
2  103, and 1  103 PFU/g, respectively (Fig. 6). To further
extend this analysis and to examine whether a delayed infec-
tion was responsible for the defective growth observed for
enhancerless virus, we determined viral titers in spleens, livers,
and lungs 14 days after infection of SCID mice with the re-
combinant viruses. At this time point, similar to what was
observed at day 7 postinfection, the titers of enhancerless
MCMV recombinants were below the levels of detection, while
parental MCMV exhibited significant viral titers in these three
organs (Fig. 6). Again, the growth properties of the revertant
FIG. 4. Excision of the BAC vector sequences from enhancerless
MCMV genomes. PCRs were performed using as templates genomic
DNAs isolated from viral stocks of MCMV (lanes 1 and 6), MCMVdE
(lanes 2 and 7), MCMVdE::Luc (lanes 3 and 8), and
MCMVdE::Luc-rev (lanes 4 and 9) or from an early MCMVdE::Luc
passage (lanes 5 and 10). Two different primer sets were used to
examine the correct excision of the BAC vector sequences within the
viral genomes. The first primer set contains a primer that anneals with
the BAC sequence and a primer located with the EcoRI g fragment
(lanes 1 to 5), and the second primer set contains two primers that bind
to viral sequences flanking the excision site (lanes 6 to 10). The am-
plified products were separated on a 1% agarose gel and visualized by
ethidium bromide staining. Shown are the products obtained in the
PCR. The positions of the size markers are shown at the left. The sizes
of the amplified products are indicated by arrows.
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virus MCMVdE::Luc-rev were very similar to those of the
parental MCMV. Consistent with the histological analysis, we
were unable to detect infectious virus in the salivary glands of
the immunocompromised mice 14 days after infection with
MCMVdE or MCMVdE::Luc (data not shown). Therefore,
these results indicate that the lack of MCMV-induced pathol-
ogy correlates with lack of replication, revealing that the en-
hancer region of MCMV is a major determinant of viral rep-
lication in vivo, at least in the target organs analyzed.
Enhancerless MCMV recombinants are severely attenuated.
The experiments detailed above indicated that recombinant
MCMVs defective in the enhancer region are severely im-
paired in the ability to grow in at least four of the major organs
targeted during CMV infection. Because the enhancer deter-
mines the efficiency of replication, we could not rule out from
these experiments the existence of enhancerless virus that
could be either replicating in sites other than the spleen, liver,
lungs, and salivary glands or present at very low levels in these
organs (below the limit of detection of the plaque assays) and
that could eventually lead to CMV disease in the host. We
therefore sought to examine the extent to which enhancerless
MCMVs were attenuated. For this purpose, the virulence of
enhancerless MCMV was compared to that of parental or
revertant MCMV by monitoring the kinetics of lethality in
SCID mice. Since it has been documented that 1 PFU of
MCMV is sufficient to kill a SCID mouse, we assessed the
virulence of enhancerless viruses by infecting these animals
with increasing concentrations of the recombinant viruses.
Mice were intraperitoneally infected with 5  100, 5  101, 5
 102, 5  103, 5  104, and 5  105 PFU of enhancerless
MCMVs, and survival was monitored daily after infection. The
mice in control groups were infected with 5 or 5  101 PFU of
parental MCMV. As shown in Fig. 7, 100% of the mice in-
fected with the parental MCMV died within 50 days after
infection. However, all the animals infected with enhancerless
viruses, with or without the stuffer sequences, survived the
infection for at least 150 days, the time at which the experiment
was terminated for most of the groups (Fig. 7). Animals in-
fected with 5  105 PFU of MCMVdE and MCMVdE:Luc
were further monitored for a total period of 365 days. During
this time, all infected mice remained alive, and infectious en-
hancerless virus could not be recovered from their main target
organs (spleen, lung, liver, and salivary glands) at the time the
animals were finally sacrificed (1 year after infection; data not
shown). Therefore, even after inoculation with 5 105 PFU of
MCMVdE or MCMVdE::Luc, a dose 105-fold higher than the
dose of wild-type MCMV that killed 100% of the mice, none of
the animals succumbed to the infection. Restoration of the
enhancer region in the revertant virus led to the rescue of the
virulence phenotype. Fifty PFU of MCMVdE::Luc-rev was
FIG. 6. Growth of enhancerless MCMV mutants in the spleens,
livers, and lungs of SCID mice. Groups of SCID mice (CB17; four to
six per group) were inoculated intraperitoneally with 6  105 PFU of
tissue culture-propagated MCMV, MCMVdE, MCMVdE::Luc, and
MCMVdE::Luc-rev. The mice were sacrificed on day 7 or 14 postin-
fection (p. i.), and their spleens, livers, and lungs were harvested for
determination of viral titers. The organs were weighed and sonicated
as a 10% (wt/vol) tissue homogenate in DMEM. The viral titers of the
resulting homogenates were determined on NIH 3T3-Bam25 cells.
Titers corresponding to the spleen, liver, and lungs from each individ-
ual mouse within a group are shown. The dashed lines represent the
limits of detection. The horizontal bars indicate the mean values.
FIG. 5. Histological examination of livers, spleens, lungs, and salivary glands from mice infected with enhancerless MCMV. Shown are sections
from livers (A to D), spleens (E and F), lungs (G and H), and salivary glands (I and J) of CB17 SCID mice 14 days after infection with 6  105
PFU of tissue culture-passaged MCMVdE::Luc (A, C, E, G, and I) or MCMVdE::Luc-rev (B, D, F, H, and J). (A, C, E, G, and I) No lesions
present. (B) Multifocal inflammatory foci (marked by arrowheads). (D) Note cytomegalic cell with inclusion (arrow). The number of inflammatory
foci present in liver sections from MCMVdE::Luc-rev-infected animals was 23  10 per mm2. (A and B) Overview; (C and D) details of portions
of A and B, respectively. (F, H, and J) Note the cytomegalic cells (indicated by arrows). (F) Neutrophilic infiltrate in splenic white pulp. (H) Lung
alveolar septal thickening with fibrin and inflammatory cells. (J) Salivary gland focal necrosis with inflammation. Bars, 400 (for A and B) and 100
(for C through J) m. Magnification, 25 (A and B) and 100 (C through J).
VOL. 77, 2003 ENHANCERLESS MCMV MUTANTS 3225
sufficient to kill all the SCID mice within 47 days (Fig. 7).
Thus, this analysis provides strong evidence that enhancerless
viruses are severely attenuated (10,000-fold difference) in the
SCID mouse model. Based on these experiments, we conclude
that the enhancer is indispensable for establishing a productive
infection in vivo.
DISCUSSION
To precisely define the role that the CMV enhancer plays in
viral growth and pathogenesis, we constructed two recombi-
nant viruses with a deletion of the complete enhancer region of
the MIEP but leaving intact the TATA box region and asso-
ciated downstream promoter-proximal regulatory sequences.
In this report, we show that the enhancer plays a critical role in
determining the rate of virus multiplication. Enhancerless vi-
ruses exhibit an MOI-dependent phenotype on permissive
NIH 3T3 cells. Under low-MOI conditions, there is a strong
requirement for viral replication, while at high MOI the en-
hancer is dispensable for growth. Remarkably we found that
genetic resection of the enhancer results in a CMV that is
completely disabled in vivo. Enhancerless viruses are non-
pathogenic and highly attenuated in immunocompromised
SCID mice. The results presented define the role of the en-
hancer in viral multiplication and pathogenesis, contributing to
a more complete understanding of the key regulatory mecha-
nisms that operate during CMV growth.
Previously, the generation of enhancerless BAC genomes
and the possibility of recovering viral progeny after transfec-
tion into permissive cells were reported (2). However, the
recombinant genomes constructed contained BAC vector se-
quences replacing an array of genes within the HindIII frag-
ment E (open reading frames m151 to m158), shown to be
dispensable for viral replication on murine fibroblasts but re-
quired for appropriate in vivo CMV growth (2, 36). Because a
major goal of this study was the analysis of the enhancer region
during infection in the natural host, we used a full-length
MCMV BAC genome (C3X) to construct two new recombi-
nant BAC genomes (MCMVdE and MCMVdE::Luc) with a
deletion of the enhancer region (base positions 	48 to 	1191
with respect to the 1 start site of MIE RNAs). In addition,
since our earlier work indicated an important function of this
region during lytic infection, we generated a stable cell line
expressing the MCMV IE proteins IE1 and IE3 and used it for
the isolation of the enhancer-deficient mutants. A relevant
feature of the enhancerless recombinant viruses obtained after
transfection in the stable cell line is an MOI dependence for
growth on permissive NIH 3T3 cells (Fig. 3A and B). These
viruses grow poorly in cells infected with single virus particles,
but high doses of virus can compensate for the most part for
the growth defect caused by the absent sequences at low MOI.
The facts that two different types of enhancerless virus exhibit
identical behavior and that restoration of the enhancer se-
quences in the revertant virus MCMVdE::Luc-rev rescues its
ability to grow in vivo indicate that this phenotype is the result
of the engineered enhancer deletion. In addition, the enhanc-
erless phenotype cannot be attributed to the loss of the puta-
tive open reading frames m124, m124.1, and m125, contained
in the deleted enhancer sequences, since a hybrid virus in
which the native MCMV enhancer is replaced by the HCMV
enhancer exhibits infectious kinetics identical to those of the
parental wild-type MCMV in cultured fibroblasts and is per-
missive in vivo (2, 13; A. Angulo and P. Ghazal, unpublished
data).
The behavior displayed by enhancer-deficient viruses is re-
markably similar to the growth phenotype reported for other
herpesvirus mutants carrying lesions within the MIE loci. For
CMV, these include mutant viruses unable to express IE1 (12,
27) or containing deletions in the distal MIEP HCMV en-
hancer (23). This MOI-dependent growth phenotype is in
agreement with the model of IE protein function which sug-
gests that the levels of IE proteins determine the outcome of a
productive CMV infection in permissive cells. In this connec-
tion, the MCMV IE3 transactivator protein has been shown to
be essential for progression to the early and late phases of
infection (1). Therefore IE3 is required to be expressed at
sufficient levels in order to push the MCMV replication cycle
forward. Of the many potential roles that the CMV enhancer
can play, it is clear that one of the most prominent functions is
to augment viral-gene expression in order to achieve IE1 and
IE3 levels sufficient to guarantee efficient entry into the lytic
cycle. Thus, under low-MOI conditions, the enhancing effect of
the enhancer is most likely revealed because MIE gene expres-
sion levels are below the threshold required to get replication
started. However, this control region might be completely dis-
pensable when increasing concentrations of virus are present
because under these conditions sufficient amounts of MIE
products are synthesized. This notion is supported in our sys-
tem by the results obtained in the complementing cell line, in
which expression of IE1 and IE3 in trans reverses the enhanc-
erless replication deficit to a significant degree (Fig. 3C).
Along this line, recent work by Meier et al. has shown that
UV-inactivated HCMV virions at a high particle/cell ratio can
overcome the defects exhibited by a virus with the distal en-
hancer deleted when grown at a low MOI (25). In this case,
virion-associated components most likely augment MIE en-
hancer promoter activity, increasing MIE gene expression
above threshold levels and compensating for the missing distal
FIG. 7. Attenuation of enhancerless MCMV mutants in SCID
mice. Groups of SCID mice (CB17; three to four mice per group) were
inoculated intraperitoneally with the indicated amounts of either pa-
rental MCMV, MCMVdE, MCMVdE::Luc, or MCMVdE::Luc-rev
and monitored daily for survival. One hundred percent of the mice that
received 5  100, 5  101, 5  102, 5  103, or 5  104 PFU of
MCMVdE or MCMVdE::Luc survived the infection for the time the
experiment lasted (150 days; data not shown).
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enhancer sequences. On the other hand, studies with the rat
CMV enhancer swap have revealed a lack of correlation be-
tween IE expression levels and viral growth in permissive cells,
reflecting the complexity and multivalency of this region and
manifesting distinct characteristics of the rat CMV enhancer
(33). Indeed, it is possible that the enhancer could play a more
direct role in promoting the rate of firing of the origin of
replication and in this capacity may be uncoupled from the
control of lytic gene expression. Clarification of the mode of
action of the enhancer will require further studies.
The impact of the enhancer region on the ability of CMV to
cause disease and eventually death was primarily explored in
SCID mice. In this model system, MCMV causes a systemic
infection replicating to high viral titers and inducing damage in
a variety of organs that include the lungs, liver, spleen, adrenal
glands, and kidneys. In this setting, viral replication is not
subjected to tight control and animals eventually succumb to as
little as 1 PFU of MCMV. Thus, the selection of this mouse
model system to evaluate the activity of enhancerless viruses
was based on the high degree of sensitivity exhibited by the
SCID mouse to infection by MCMV. In initial experiments, we
failed to detect infectious virus in a variety of organs of immu-
nocompetent BALB/c mice after infection with enhancerless
viruses (data not shown). Three lines of evidence firmly sup-
port the notion that the enhancer region is indispensable dur-
ing the course of acute MCMV infection. First, histological
examination of a variety of organs of MCMVdE- and
MCMVdE::Luc-infected animals resulted in the absence of
detectable MCMV-induced associated damage (Fig. 5). Sec-
ond, enhancerless viruses failed to replicate to detectable lev-
els in the major target organs for CMV replication (Fig. 6).
And finally, MCMVdE and MCMVdE::Luc were unable to kill
SCID mice even when the animals were infected at a dose 105
times higher than the dose of parental MCMV required to
cause death (Fig. 7). The finding that two different enhancer-
less viruses, MCMVdE and MCMdE::Luc, exhibited identical
behavior, together with the fact that repairing this region in
MCMVdE::Luc-rev restored virus-induced damage and viru-
lence to the wild-type level, indicate that this attenuated phe-
notype can be attributed to the deletion of the enhancer.
Due to the robust growth of enhancerless virus in cultured
cells at high MOI, the absolute requirement for the enhancer
for CMV replication in immunocompromised mice was not
anticipated. Our in vivo results using high viral doses do not
even parallel events occurring in cells infected with single virus
particles. Thus, the residual activity of enhancerless viruses
exhibited in permissive NIH 3T3 cells and mouse embryonic
fibroblasts (data not shown) under low-MOI conditions does
not seem to be sufficient to establish or maintain low-level
replication in vivo. It is noteworthy that while the SCID mice
are deficient in T, B, and NK (Ly49) cells, they retain a certain
degree of innate immunity. Thus, one possible corollary from
these observations is that the enhancer plays a critical role in
driving an infection past the initial innate response of SCID
mice. Alternatively, it is possible that enhancerless virus may
manifest a more cell-type-specific effect, such as replication
deficiency in macrophages, that severely compromises dissem-
ination and the establishment of productive infection. How-
ever, when injected intravenously into SCID mice, enhancer-
less viruses failed to replicate to detectable levels in the spleen
and liver during a 3-day period (data not shown). Nevertheless,
in our studies, we cannot rule out the presence of low levels of
enhancerless virus replication (below our levels of detection)
in certain cell types in SCID mice, which would be kept in
check by T- and B-lymphocyte- and NK cell-independent
mechanisms. In this sense, the use of alternative and more
sensitive techniques to detect infected cells in mouse tissues,
such as the one described by Grzimek and coworkers (13),
might be of great help in addressing this issue. Finally, one has
to consider the limitations of the animal model used in this
study and the possibility that enhancerless viruses would rep-
licate to some extent in the complete absence of immune
functions.
Due to the strict species specificity associated with CMV, the
study of MCMV in its natural host has been extensively used to
address many aspects of HCMV pathogenesis. Whether the
observations reported here in the murine model might be ex-
tended to the HCMV enhancer remains an open question.
While different at the primary sequence level, MCMV and
HCMV enhancers share many of the same regulatory elements
(such as NF-B, retinoic acid receptors, AP-1, and CREB/
ATF). At the in vitro level, MCMV and HCMV containing
deletions in the enhancer region exhibit very similar pheno-
types (23). Furthermore, the fact that the human enhancer can
replace the natural MCMV enhancer-promoter in vitro and in
vivo suggests a functional conservation of this control region in
the two species (2, 13). These findings, in concert with the
results presented here demonstrating the lack of residual abil-
ity of enhancer-deficient genomes to replicate in vivo, establish
the basis for the use of enhancer swap strains as tools for the
identification of functional HCMV enhancer elements in the
context of mouse infection. Viral mutants containing subtle
mutations in the transcription binding sites within this control
region can now be engineered in order to dissect the contri-
butions that the different signaling pathways may make to
CMV pathogenesis.
In summary, our results clearly document an absolutely es-
sential role of the MCMV enhancer during acute infection.
These findings indicate that this regulatory region might be a
good target for antiviral therapy, as blocking enhancer activity
should eliminate or lessen the burden of CMV infection and
disease. The severe attenuated phenotype suggests novel vac-
cine approaches or gene therapy agents. Further studies will be
required to thoroughly understand how this complicated con-
trol region operates.
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